MaxCyte, Inc. (MXCT) Financial Statements
MaxCyte, Inc. (MXCT) reported trailing twelve-month revenue of $31.1M (down 13.2% year on year) and net income of -$35.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$23.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 144.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 14 Oct; these figures move once the 10-Q is filed.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 33.9 | 44.3 | 41.3 | 38.6 | 33.0 | 31.1 | |
| Gross profit | 30.2 | 39.2 | 36.5 | 31.5 | 26.8 | 24.6 | |
| Research & development | 15.4 | 19.5 | 23.8 | 22.2 | 20.8 | 16.8 | |
| Operating income | -18.2 | -27.4 | -48.3 | -51.2 | -51.9 | -41.8 | |
| Pre-tax income | -19.1 | — | — | -41.1 | -44.6 | -35.6 | |
| Income tax | 0.0 | — | — | — | — | — | |
| Net income | -19.1 | -23.6 | -37.9 | -41.1 | -44.6 | -35.6 | |
| Diluted EPS ($) | -0.21 | -0.23 | -0.37 | -0.39 | -0.42 | -0.33 | |
| Diluted shares (mn) | 90.6 | 101.7 | 103.3 | 104.8 | 106.4 | — |
USD millions · SEC XBRL
MaxCyte, Inc. — questions
- What is MaxCyte, Inc.'s revenue?
- $31.1M over the twelve months to 2026-06-30, down 13.2% year on year, from its 10-Q and 10-K filings.
- What is MaxCyte, Inc.'s net income?
- -$35.6M over the twelve months to 2026-06-30.
- What is MaxCyte, Inc.'s free cash flow?
- -$23.6M over the twelve months to 2026-06-30.
- What are MaxCyte, Inc.'s diluted earnings per share?
- $-0.33 over the twelve months to 2026-06-30.
Every figure on this page comes from MaxCyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.